ScholarIQanswers from OpenAlex & ORCID
Howard S. Höchster
ResearcherPublications, citations & collaboration network
Howard S. Höchster is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Howard S. Höchster have?
ScholarIQindexed works
Howard S. Höchster has 582 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Howard S. Höchster have?
ScholarIQcitation count
Howard S. Höchster has 24,718 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Howard S. Höchster?
ScholarIQh-index
Howard S. Höchster has an h-index of 72 in OpenAlex.
What is the i10-index of Howard S. Höchster?
ScholarIQi10-index
Howard S. Höchster has an i10-index of 214 in OpenAlex.
What is the ORCID of Howard S. Höchster?
ScholarIQorcid
The ORCID for Howard S. Höchster is on the source record.
What is the OpenAlex record for Howard S. Höchster?
ScholarIQopenalex
The OpenAlex for Howard S. Höchster is on the source record.
What are the most-cited papers on Howard S. Höchster?
ScholarIQmost cited works
VEGF Inhibition and Renal Thrombotic Microangiopathy
Vera Eremina, J. Ashley Jefferson, Jolanta Kowalewska, Howard S. Höchster, Mark Haas, Joseph Weisstuch, C. A. Richardson, Jeffrey B. Kopp, M. Golam Kabir, Peter H. Backx, Hans-Peter Gerber, N. Ferrara, Laura Barisoni, Charles E. Alpers, Susan E. Quaggin
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Charlotte Jacobs, Gary H. Lyman, E Vélez-García, K. S. Sridhar, W. Andy Knight, Howard S. Höchster, Lawrence T. Goodnough, Joanne Mortimer, L H Einhorn, Lee Schacter
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee, Y-J. Bang, Johanna C. Bendell, Yee Chao, J-S Chen, Hyun Cheol Chung, S. Lindsey Davis, Atul Dev, Edward Gane, Ben George, Aiwu Ruth He, Howard S. Höchster, C-H Hsu, Masafumi Ikeda, Jes Chauviere Lee, M. Lee, Amit Mahipal, Gulam A. Manji, Manabu Morimoto, Kazushi Numata, Michael J. Pishvaian, Shukui Qin, David P. Ryan, B-Y Ryoo, Naoki Sasahira, Stacey Stein, John H. Strickler, N. C. Tebbutt
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
Arvind Dasari, Van K. Morris, Carmen J. Allegra, Chloé E. Atreya, Al B. Benson, Patrick M. Boland, Ki Yong Chung, Mehmet Sitki Copur, Ryan B. Corcoran, Dustin A. Deming, Andrea Dwyer, Maximilian Diehn, Cathy Eng, Thomas J. George, Marc J. Gollub, Rachel Goodwin, Stanley R. Hamilton, Jaclyn F. Hechtman, Howard S. Höchster, Theodore S. Hong, Federico Innocenti, Atif Iqbal, Samuel A. Jacobs, Hagen F. Kennecke, James J. Lee, Christopher H. Lieu, Heinz‐Josef Lenz, O. Wolf Lindwasser, Clara Montagut, Bruno C. Odisio, Fang‐Shu Ou, Laura Porter, Kanwal Raghav, Deborah Schrag, Aaron J. Scott, Qian Shi, John H. Strickler, Alan P. Venook, Rona Yaeger, Greg Yothers, Y. Nancy You, Jason A. Zell, Scott Kopetz